Vor Bio To Participate in Upcoming September Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:
- Wells Fargo 21st Annual Healthcare Conference
Forum: Fireside Chat and 1x1 Meetings
Date: Tuesday, September 8th
Presentation Time: 8:00AM ET
- Citi’s 2026 Biopharma Back to School Conference
Forum: Fireside Chat and 1x1 Meetings
Date: Wednesday, September 9th
Presentation Time: 11:20AM ET
- Morgan Stanley 24th Annual Global Healthcare Conference
Forum: 1x1 Meetings
Date: Monday, September 14th
- Baird’s 2026 Global Healthcare Conference
Forum: Presentation and 1x1 Meetings
Date: Tuesday, September 15th
Presentation Time: 9:05AM ET
- Stifel’s 2026 Virtual Immunology and Inflammation Forum
Forum: Presentation and 1x1 Meetings
Date: Wednesday, September 23rd
Presentation Time: 11:30AM ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States